Patents by Inventor Ekaterina Doubrovina
Ekaterina Doubrovina has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220023417Abstract: Disclosed herein are methods of selecting an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer. Also disclosed are methods of selecting a donor from whom to derive an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer.Type: ApplicationFiled: October 8, 2021Publication date: January 27, 2022Applicant: Memorial Sloan Kettering Cancer CenterInventors: Richard J. O'Reilly, Ekaterina Doubrovina, Guenther Koehne, Aisha N. Hasan, Susan E. Prockop
-
Patent number: 11173205Abstract: Disclosed herein are methods of selecting an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer. Also disclosed are methods of selecting a donor from whom to derive an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer.Type: GrantFiled: November 4, 2015Date of Patent: November 16, 2021Assignee: Memorial Sloan Kettering Cancer CenterInventors: Richard J. O'Reilly, Ekaterina Doubrovina, Guenther Koehne, Aisha N. Hasan, Susan E. Prockop
-
Patent number: 11103577Abstract: Methods of treating CMV (cytomegalovirus) retinitis in a human patient in need thereof comprise administering to the human patient a population of allogeneic T cells comprising CMV-specific T cells, wherein the human patient is infected with human immunodeficiency virus (HIV) or has been the recipient of a solid organ transplant.Type: GrantFiled: May 23, 2019Date of Patent: August 31, 2021Assignees: Memorial Sloan Kettering Cancer Center, Cornell UniversityInventors: Richard John O'Reilly, Susan Elizabeth Prockop, Ekaterina Doubrovina, Guenther Koehne, Aisha Nasreen Hasan, Szilard Kiss
-
Publication number: 20210000874Abstract: Provided herein are methods of selecting a T cell line from among a collection of T cell lines for therapeutic administration to a human patient to treat a disease or disorder associated with a pathogen or to treat a cancer in the human patient. When the human patient has not been the recipient of any cellular transplant, the method involves excluding T cell lines restricted by only one HLA allele shared with the human patient and selecting a T cell line that is restricted to more than one HLA allele shared with the human patient and that exhibits a T cell response against an antigen of the pathogen or cancer.Type: ApplicationFiled: March 13, 2019Publication date: January 7, 2021Applicant: Memorial Sloan Kettering Cancer CenterInventors: Richard John O'Reilly, Ekaterina Doubrovina, Susan Elizabeth Prockop
-
Patent number: 10815274Abstract: This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a WT-1-expressing cancer, comprising peptides derived from the WT-1 protein.Type: GrantFiled: September 7, 2018Date of Patent: October 27, 2020Assignee: MEMORIAL SLOAN KETTERING CANCER CENTERInventors: Richard O'Reilly, Ekaterina Doubrovina, Annamalai Selvakumar
-
Patent number: 10568908Abstract: The invention relates to methods of treating an EBV-LPD (Epstein-Barr Virus-associated lymphoproliferative disorder) in a human patient who has failed combination chemotherapy to treat the EBV-LPD and/or radiation therapy to treat the EBV-LPD, comprising administering to the human patient a population of allogeneic T cells comprising EBV-specific T cells.Type: GrantFiled: May 11, 2016Date of Patent: February 25, 2020Assignee: Memorial Sloan Kettering Cancer CenterInventors: Richard John O'Reilly, Susan Elizabeth Prockop, Aisha Nasreen Hasan, Ekaterina Doubrovina
-
Publication number: 20200017586Abstract: Provided herein are methods of treating a human patient, comprising administering to the human patient an inhibitory immune checkpoint inhibitor or stimulatory immune checkpoint activator and administering to the human patient a population of human cells comprising antigen-specific T cells that are derived from a T cell line restricted by a subdominant HLA allele or HLA allele combination. Also provided are methods of selecting such a T cell line and methods of selecting a T cell donor from whom to derive such a T cell line, for therapeutic administration to a human patient in combination with administration of an inhibitory immune checkpoint inhibitor or stimulatory immune checkpoint activator. Also provided are pharmaceutical compositions comprising an inhibitory immune checkpoint inhibitor or stimulatory immune checkpoint activator and a population of human cells comprising antigen-specific T cells that are derived from a T cell line restricted by a subdominant HLA allele or HLA allele combination.Type: ApplicationFiled: February 6, 2018Publication date: January 16, 2020Applicant: Memorial Sloan Kettering Cancer CenterInventors: Richard John O'Reilly, Susan Elizabeth Prockop, Ekaterina Doubrovina, Parastoo Bahrami Dahi
-
Publication number: 20200016261Abstract: Disclosed herein are methods of treating CMV (cytomegalovirus) retinitis in a human patient in need thereof, comprising administering to the human patient a population of allogeneic T cells comprising CMV-specific T cells, wherein the human patient is infected with HIV or has been the recipient of a solid organ transplant.Type: ApplicationFiled: May 23, 2019Publication date: January 16, 2020Applicants: Memorial Sloan Kettering Cancer Center, Cornell UniversityInventors: Richard John O'Reilly, Susan Elizabeth Prockop, Ekaterina Doubrovina, Guenther Koehne, Aisha Nasreen Hasan, Szilard Kiss
-
Patent number: 10342864Abstract: Methods of treating CMV (cytomegalovirus) retinitis in a human patient in need thereof, comprising administering to the human patient a population of allogeneic T cells comprising CMV-specific T cells, wherein the human patient is infected with human immunodeficiency virus (HIV) or has been the recipient of a solid organ transplant.Type: GrantFiled: June 24, 2016Date of Patent: July 9, 2019Assignees: Memorial Sloan Kettering Cancer Center, Cornell UniversityInventors: Richard John O'Reilly, Susan Elizabeth Prockop, Ekaterina Doubrovina, Guenther Koehne, Aisha Nasreen Hasan, Szilard Kiss
-
Publication number: 20190092813Abstract: This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a WT-1-expressing cancer, comprising peptides derived from the WT-1 protein.Type: ApplicationFiled: September 7, 2018Publication date: March 28, 2019Applicant: Memorial Sloan Kettering Cancer CenterInventors: Richard O'REILLY, EKATERINA DOUBROVINA, ANNAMALAI SELVAKUMAR
-
Patent number: 10100087Abstract: This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a WT-1-expressing cancer, comprising peptides derived from the WT-1 protein.Type: GrantFiled: May 30, 2017Date of Patent: October 16, 2018Assignee: Memorial Sloan Kettering Cancer CenterInventors: Richard J. O'Reilly, Ekaterina Doubrovina, Annamalai Selvakumar
-
Publication number: 20180125891Abstract: Disclosed herein are methods of treating an EBV-LPD (Epstein-Barr Virus-associated lymphoproliferative disorder) in a human patient who has failed combination chemotherapy to treat the EBV-LPD and/or radiation therapy to treat the EBV-LPD, comprising administering to the human patient a population of allogeneic T cells comprising EBV-specific T cells.Type: ApplicationFiled: May 12, 2015Publication date: May 10, 2018Applicant: Memorial Sloan Kettering Cancer CenterInventors: Richard John O'Reilly, Susan Elizabeth Prockop, Aisha Nasreen Hasan, Ekaterina Doubrovina
-
Publication number: 20170334951Abstract: This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a WT-1-expressing cancer, comprising peptides derived from the WT-1 protein.Type: ApplicationFiled: May 30, 2017Publication date: November 23, 2017Applicant: Memorial Sloan Kettering Cancer CenterInventors: Richard J. O'Reilly, Ekaterina Doubrovina, Annamalai Selvakumar
-
Publication number: 20170319683Abstract: Disclosed herein are methods of selecting an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer. Also disclosed are methods of selecting a donor from whom to derive an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer.Type: ApplicationFiled: November 4, 2015Publication date: November 9, 2017Applicant: Memorial Sloan Kettering Cancer CenterInventors: Richard J. O'Reilly, Ekaterina Doubrovina, Guenther Koehne, Aisha N. Hasan, Susan E. Prockop
-
Publication number: 20170128565Abstract: Disclosed herein are methods of treating CMV (cytomegalovirus) retinitis in a human patient in need thereof, comprising administering to the human patient a population of allogeneic T cells comprising CMV-specific T cells, wherein the human patient is infected with HIV or has been the recipient of a solid organ transplant.Type: ApplicationFiled: June 24, 2016Publication date: May 11, 2017Applicants: Memorial Sloan Kettering Cancer Center, Cornell UniversityInventors: Richard John O'Reilly, Susan Elizabeth Prockop, Ekaterina Doubrovina, Guenther Koehne, Aisha Nasreen Hasan, Szilard Kiss
-
Publication number: 20160375060Abstract: Disclosed herein are methods of treating glioblastoma multiforme (GBM) in a human patient in need thereof, comprising administering to the human patient a population of allogeneic T cells comprising CMV (cytomegalovirus)-specific T cells.Type: ApplicationFiled: June 24, 2016Publication date: December 29, 2016Applicant: Memorial Sloan Kettering Cancer CenterInventors: Richard John O'Reilly, Aisha Nasreen Hasan, Guenther Koehne, Ekaterina Doubrovina
-
Publication number: 20150104413Abstract: This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a WT-1-expressing cancer, comprising peptides derived from the WT-1 protein.Type: ApplicationFiled: January 14, 2013Publication date: April 16, 2015Applicant: MEMORIAL SLOAN KETTERING CANCER CENTERInventors: Richard J. O'Reilly, Ekaterina Doubrovina, Annamalai Selvakumar